Heterologous vaccine interventions: boosting immunity against future pandemics

Molecular Medicine

Nathaniel Hupert¹  Douglas F. Nixon²  Daniela Marín-Hernández² 

[1] Department of Population Health Sciences, Weill Cornell Medicine, 402 E. 67th Street, 10065, New York, NY, USA;Cornell Institute for Disease and Disaster Preparedness, Weill Cornell Medicine, 402 E. 67th Street, 10065, New York, NY, USA;Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, Belfer Research Building, Room 530, 413 E. 69th street, 10065, New York, NY, USA;

关键词: Vaccine;    Non-specific immunity;    Innate immunity;    Trained immunity;    BCG;    Influenza vaccine;    Vaccination;    Heterologous;   

DOI  :  10.1186/s10020-021-00317-z

来源: Springer

【 摘 要 】

While vaccines traditionally have been designed and used for protection against infection or disease caused by one specific pathogen, there are known off-target effects from vaccines that can impact infection from unrelated pathogens. The best-known non-specific effects from an unrelated or heterologous vaccine are from the use of the Bacillus Calmette-Guérin (BCG) vaccine, mediated partly through trained immunity. Other vaccines have similar heterologous effects. This review covers molecular mechanisms behind the heterologous effects, and the potential use of heterologous vaccination in the current COVID-19 pandemic. We then discuss novel pandemic response strategies based on rapidly deployed, widespread heterologous vaccination to boost population-level immunity for initial, partial protection against infection and/or clinical disease, while specific vaccines are developed.

【 授权许可】

CC BY